Latest Information Update: 17 Nov 2003
At a glance
- Originator Rodlen Laboratories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pruritus
Most Recent Events
- 04 Dec 2002 unspecified for Pruritus in United Kingdom (unspecified route)
- 05 Dec 2001 Preclinical development for Pruritus in United Kingdom (Unknown route)